公开(公告)号：US11267821B2

公开(公告)日：2022-03-08

申请号：US16807335

申请日：2020-03-03

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yoshiaki Ohashi ,  Yoshihiko Norimine ,  Tamaki Hoshikawa ,  Yu Yoshida ,  Yoshihisa Kobayashi ,  Nobuhiro Sato ,  Koji Hagiwara ,  Nobuaki Sato ,  Shinsuke Hirota ,  Takaaki Harada ,  Hikaru Yoshimura

IPC: C07D495/22 ,  A61K31/551 ,  A61P25/00 ,  C07D491/22 ,  C07D491/147

Abstract: The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:

公开(公告)号：US09458176B2

公开(公告)日：2016-10-04

申请号：US14190356

申请日：2014-02-26

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mamoru Takaishi ,  Nobuhiro Sato ,  Tomoyuki Shibuguchi ,  Takafumi Motoki ,  Yoshinori Takahashi ,  Takeo Sasaki ,  Alan Braunton

IPC: A61K31/553 ,  C07D498/04

CPC classification number: C07D498/04

Abstract: A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof works as an mGluR2 antagonist, and is applicable as a therapeutic agent for neurological disorders related to glutamate dysfunction and diseases involving the mGluR2, such as Alzheimer's disease: wherein R is a hydrogen atom, a C1-6 alkyl group or the like, R1 is a C1-6 alkyl group, a C1-6 alkoxy group or the like, R2 is a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or the like, R3 is a hydrogen atom, a C1-6 alkyl group or the like, and R4 is a C1-6 alkyl group or the like.

公开(公告)号：US20140243316A1

公开(公告)日：2014-08-28

申请号：US14190356

申请日：2014-02-26

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mamoru Takaishi ,  Nobuhiro Sato ,  Tomoyuki Shibuguchi ,  Takafumi Motoki ,  Yoshinori Takahashi ,  Takeo Sasaki ,  Alan Braunton

IPC: C07D498/04

CPC classification number: C07D498/04

Abstract: A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof works as an mGluR2 antagonist, and is applicable as a therapeutic agent for neurological disorders related to glutamate dysfunction and diseases involving the mGluR2, such as Alzheimer's disease: wherein R is a hydrogen atom, a C1-6 alkyl group or the like, R1 is a C1-6 alkyl group, a C1-6 alkoxy group or the like, R2 is a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or the like, R3 is a hydrogen atom, a C1-6 alkyl group or the like, and R4 is a C1-6 alkyl group or the like.

Abstract translation: 由下式（I）表示的化合物或其药学上可接受的盐作为mGluR2拮抗剂起作用，可用作与谷氨酸功能障碍相关的神经障碍和涉及mGluR2的疾病如阿尔茨海默氏病的治疗剂：其中R为 氢原子，C 1-6烷基等，R 1为C 1-6烷基，C 1-6烷氧基等，R 2为卤素原子，C 1-6烷基，C 1-6 烷氧基等，R3是氢原子，C1-6烷基等，R4是C1-6烷基等。

公开(公告)号：US11358972B2

公开(公告)日：2022-06-14

申请号：US16807335

申请日：2020-03-03

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yoshiaki Ohashi ,  Yoshihiko Norimine ,  Tamaki Hoshikawa ,  Yu Yoshida ,  Yoshihisa Kobayashi ,  Nobuhiro Sato ,  Koji Hagiwara ,  Nobuaki Sato ,  Shinsuke Hirota ,  Takaaki Harada ,  Hikaru Yoshimura

IPC: C07D495/22 ,  A61K31/551 ,  A61P25/00 ,  C07D491/22 ,  C07D491/147

Abstract: The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:

公开(公告)号：US20200283452A1

公开(公告)日：2020-09-10

申请号：US16807335

申请日：2020-03-03

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yoshiaki Ohashi ,  Yoshihiko Norimine ,  Tamaki Hoshikawa ,  Yu Yoshida ,  Yoshihisa Kobayashi ,  Nobuhiro Sato ,  Koji Hagiwara ,  Nobuaki Sato ,  Shinsuke Hirota ,  Takaaki Harada ,  Hikaru Yoshimura

IPC: C07D495/22 ,  C07D491/147 ,  C07D491/22

Abstract: The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:

公开(公告)号：US10239889B1

公开(公告)日：2019-03-26

申请号：US16122116

申请日：2018-09-05

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yoshiaki Ohashi ,  Yoshihiko Norimine ,  Tamaki Hoshikawa ,  Yu Yoshida ,  Yoshihisa Kobayashi ,  Nobuhiro Sato ,  Koji Hagiwara

IPC: A61K31/551 ,  A61P25/00 ,  C07D495/22 ,  A61P25/16 ,  A61P25/28

Abstract: The present invention provides compounds represented by formulas (1) to (VI) or pharmaceutically acceptable salts thereof:

公开(公告)号：US20190071452A1

公开(公告)日：2019-03-07

申请号：US16122116

申请日：2018-09-05

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yoshiaki Ohashi ,  Yoshihiko Norimine ,  Tamaki Hoshikawa ,  Yu Yoshida ,  Yoshihisa Kobayashi ,  Nobuhiro Sato ,  Koji Hagiwara

IPC: C07D495/22 ,  A61P25/28 ,  A61P25/16

Abstract: The present invention provides compounds represented by formulas (I) to (VI) or pharmaceutically acceptable salts thereof.

公开(公告)号：US20160052937A1

公开(公告)日：2016-02-25

申请号：US14830970

申请日：2015-08-20

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mamoru Takaishi ,  Nobuhiro Sato ,  Takafumi Motoki ,  Tomoyuki Shibuguchi

IPC: C07D498/04

CPC classification number: C07D498/04

Abstract: A compound represented by formula (I): wherein R is a methyl group or the like, R1 is a fluorine atom or the like, R2 is a hydrogen atom or a fluorine atom, R3 is a hydrogen atom, R4 is an ethyl group or the like, or a pharmaceutically acceptable salt thereof.

Abstract translation: 由式（I）表示的化合物：其中R是甲基等，R 1是氟原子等，R 2是氢原子或氟原子，R 3是氢原子，R 4是乙基或 或其药学上可接受的盐。